TheEdgeResearch
Home / Stocks / CLYYF

Celyad Oncology S.A. (CLYYF)

OTC Healthcare Biotechnology
$0.28 ▲ +0.00%
Market Cap
$13.2M
Sector
Healthcare
Industry
Biotechnology
Beta
1.21
52-Wk Range
0.15-0.35
CEO
Michel E. J. Lussier
Country
BE
Currency
USD

Celyad Oncology S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mont-Saint-Guibert, WA, BE. The stock last traded at $0.28, up 0.00% on the session, giving a market capitalisation of $13.2M. On trailing twelve-month figures it carries a trailing P/E of 1.95, a net margin of 47071.4%. Its beta of 1.21 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
1.95
Price / Sales
1093.78
Price / Book
5.77
EV / EBITDA
-1.61
Gross margin
29800.0%
Operating margin
-68728.6%
Net margin
47071.4%
Return on equity
—
Debt / equity
0.02
Current ratio
0.94
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
17
IPO date
2014-01-15
Headquarters
Mont-Saint-Guibert, WA, BE
About Celyad Oncology S.A.

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Comparable companies

Celyad Oncology S.A. is most often compared with the following Healthcare names:

ADTXALLRBWVCHNXFCLAZFERYPFORUHILSIPCIFKPRX
More research on CLYYF
CLYYF technical analysis CLYYF TheEdge Score Compare against peers
Open full interactive analysis & DCF →